期刊文献+

艾拉莫德与双醋瑞因对难治性类风湿关节炎患者的疗效及其对炎症因子和超氧化歧化酶等指标水平的影响 被引量:10

下载PDF
导出
摘要 目的:评价艾拉莫德与双醋瑞因对难治性类风湿关节炎(RRA)患者的疗效及其对炎症因子和超氧化歧化酶(SOD)等指标水平的影响。方法:选取2015年8月—2016年8月间就诊治疗的RRA患者106例资料,将其分为常规组和治疗组,每组53例;常规组患者给予甲氨蝶呤与艾拉莫德治疗,而治疗组患者则给予艾拉莫德和双醋瑞因治疗,比较两组患者治疗后白介素-1(IL-1)、肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)、血管内皮生长因子(VEGF)、丙二醛(MDA)、SOD、总抗氧化能力(TAOC)指标水平测得值的变化情况,以及用药期间不良反应的发生率差异。结果:治疗后治疗组患者的IL-1、TNF-α、CRP、VEGF、MDA、TAOC水平测得值低于常规组(P<0.05),SOD水平测得值高于常规组(P<0.05);两组患者治疗期间的不良反应发生率经组间比较其差异无统计学意义(P>0.05)。结论:采用艾拉莫德和双醋瑞因治疗RRA患者的疗效较为确切,有效改善了炎症因子和SOD等指标水平,促进了RRA的康复。
作者 黎声飞
出处 《抗感染药学》 2018年第1期153-155,共3页 Anti-infection Pharmacy
  • 相关文献

参考文献6

二级参考文献70

  • 1Aletaha D, Neogi T, Silman A J, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collab- orative initiative[J]. Arthritis Rheum, 2010, 62(9): 2569. 被引量:1
  • 2Smolen J S, Aletaha D, Bijlsma J W J, et al. Treating rheumatoid arthritis to target: recommendations of an inter national task force[J]. Ann Rheum Dis, 2010, 69(4) : 631. 被引量:1
  • 3Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBI- TION study[J]. Ann Rheum Dis, 2010, 69(01): 88. 被引量:1
  • 4Fleisehmann R, Kremer J, Cush J, et al. Placebo con- trolled trial of tofacitinib monotherapy in rheumatoid arthritis [J]. N EnglJ Med, 2012, 367(6): 495. 被引量:1
  • 5Sellam J, Hendel Chavez H, Roumlet S, et al. B ceil activa- tion biomarkers as predictive factors for the response to ritux- imab in rheumatoid arthritis: A six month, national, multi- center, open label study[J]. Arthritis Rheum, 2011, 63 (4): 933. 被引量:1
  • 6Kremer J M, Blanco R, Brzosko M, et al. Tocilizumab in- hibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double blind treatment phase of a randomized placebo con- trolled trial of tocilizumab safety and prevention of structural joint danmge at one year[J]. Arthritis Rheum, 2011, 63 (3) : 609. 被引量:1
  • 7Moreland L W, O'Dell J R, Paulus H E, et al. A random- ized comparative effectiveness study of oral triple therapy ver sus etanercept plus methotrexate in early aggressive rheuma toid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial[J]. Arthritis Rheum, 2012, 64(9): 2824. 被引量:1
  • 8Du F, Lv LJ, Fu Q, et al. T-614, a novel immu-nomodulator, attenuates joint inflammation and art-icular damage in collageninduced arthritis [ J ]. Arthritis Res Therapy ,2008,10 (6) : R136. 被引量:1
  • 9Aikawa Y, Yamamoto M, Yamamoto T, et al. An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS-an d TNF-alph-stimulated THP-1 cells without interfering with Ikappa B-alpha degradation [ J ]. Inflamm Res ,2002,51 (4) : 188-194. 被引量:1
  • 10Inaba T,Tanaka K,Takeno R,et al. Synthesis and antiinfl- amatory ac- tivity of 7-methanesulfonylamino-6-phenoxychromon-es: antiarthritie effect of the 3-formylamino compound(T-614) in chronic inflammatory disease models [ J ]. Chem Pharm Bull ( Tokyo ), 2000, 48 ( 1 ) : 131-139. 被引量:1

共引文献120

同被引文献114

引证文献10

二级引证文献62

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部